Autopsy report · NCT02087085
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 11 months before it stopped.
- 310 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Allergan
- Sponsor type
- Industry
- Conditions
- Geographic Atrophy; Macular Degeneration
- Interventions
- 400 µg Brimonidine Implant; Sham
- Participants
- 310
- Sites
- 41
- Countries
- Australia, France, Germany, Italy, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.